Drugs / ADCE-B05
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07362888 | Mar → Dec 2026 expected | — | Adcendo ApS | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADCE-B05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07362888 ↗ |
| Route | Intravenous | “ADCE-B05 is administered intravenously on a 3 weekly dosing cycle” NCT07362888 ↗ |